vs
Side-by-side financial comparison of ONESPAWORLD HOLDINGS Ltd (OSW) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
ONESPAWORLD HOLDINGS Ltd is the larger business by last-quarter revenue ($242.1M vs $177.4M, roughly 1.4× Pacira BioSciences, Inc.). ONESPAWORLD HOLDINGS Ltd runs the higher net margin — 5.0% vs 1.6%, a 3.3% gap on every dollar of revenue. On growth, ONESPAWORLD HOLDINGS Ltd posted the faster year-over-year revenue change (11.5% vs 5.0%). Over the past eight quarters, ONESPAWORLD HOLDINGS Ltd's revenue compounded faster (7.1% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
OSW vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $242.1M | $177.4M |
| Net Profit | $12.1M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 6.8% | 3.9% |
| Net Margin | 5.0% | 1.6% |
| Revenue YoY | 11.5% | 5.0% |
| Net Profit YoY | -16.2% | — |
| EPS (diluted) | $0.12 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $242.1M | $196.9M | ||
| Q3 25 | $258.5M | $179.5M | ||
| Q2 25 | $240.7M | $181.1M | ||
| Q1 25 | $219.6M | $168.9M | ||
| Q4 24 | $217.2M | $187.3M | ||
| Q3 24 | $241.7M | $168.6M | ||
| Q2 24 | $224.9M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $12.1M | — | ||
| Q3 25 | $24.3M | $5.4M | ||
| Q2 25 | $19.9M | $-4.8M | ||
| Q1 25 | $15.3M | $4.8M | ||
| Q4 24 | $14.4M | — | ||
| Q3 24 | $21.6M | $-143.5M | ||
| Q2 24 | $15.8M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 6.8% | 1.2% | ||
| Q3 25 | 10.2% | 3.5% | ||
| Q2 25 | 9.2% | 4.7% | ||
| Q1 25 | 7.7% | 1.2% | ||
| Q4 24 | 7.9% | 13.2% | ||
| Q3 24 | 10.3% | -82.8% | ||
| Q2 24 | 8.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 5.0% | — | ||
| Q3 25 | 9.4% | 3.0% | ||
| Q2 25 | 8.3% | -2.7% | ||
| Q1 25 | 7.0% | 2.8% | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | 8.9% | -85.1% | ||
| Q2 24 | 7.0% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.12 | $0.05 | ||
| Q3 25 | $0.23 | $0.12 | ||
| Q2 25 | $0.19 | $-0.11 | ||
| Q1 25 | $0.15 | $0.10 | ||
| Q4 24 | $0.13 | $0.38 | ||
| Q3 24 | $0.20 | $-3.11 | ||
| Q2 24 | $0.15 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.3M | $144.3M |
| Total DebtLower is stronger | $84.0M | — |
| Stockholders' EquityBook value | $542.6M | $653.9M |
| Total Assets | $707.1M | $1.2B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $16.3M | $238.4M | ||
| Q3 25 | $29.6M | $246.3M | ||
| Q2 25 | $35.0M | $445.9M | ||
| Q1 25 | $22.6M | $493.6M | ||
| Q4 24 | $57.4M | $484.6M | ||
| Q3 24 | $48.8M | $453.8M | ||
| Q2 24 | $62.5M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $84.0M | $372.2M | ||
| Q3 25 | $85.2M | $376.7M | ||
| Q2 25 | $96.2M | $580.5M | ||
| Q1 25 | $97.4M | $583.4M | ||
| Q4 24 | $98.6M | $585.3M | ||
| Q3 24 | $98.7M | — | ||
| Q2 24 | $123.8M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $542.6M | $693.1M | ||
| Q3 25 | $552.8M | $727.2M | ||
| Q2 25 | $548.3M | $757.8M | ||
| Q1 25 | $530.6M | $798.5M | ||
| Q4 24 | $554.5M | $778.3M | ||
| Q3 24 | $540.1M | $749.6M | ||
| Q2 24 | $532.7M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $707.1M | $1.3B | ||
| Q3 25 | $732.6M | $1.3B | ||
| Q2 25 | $731.8M | $1.5B | ||
| Q1 25 | $708.7M | $1.6B | ||
| Q4 24 | $746.4M | $1.6B | ||
| Q3 24 | $734.0M | $1.5B | ||
| Q2 24 | $756.8M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | 0.54× | ||
| Q3 25 | 0.15× | 0.52× | ||
| Q2 25 | 0.18× | 0.77× | ||
| Q1 25 | 0.18× | 0.73× | ||
| Q4 24 | 0.18× | 0.75× | ||
| Q3 24 | 0.18× | — | ||
| Q2 24 | 0.23× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.0M | — |
| Free Cash FlowOCF − Capex | $14.9M | — |
| FCF MarginFCF / Revenue | 6.2% | — |
| Capex IntensityCapex / Revenue | 2.1% | — |
| Cash ConversionOCF / Net Profit | 1.65× | — |
| TTM Free Cash FlowTrailing 4 quarters | $68.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $20.0M | $43.7M | ||
| Q3 25 | $33.2M | $60.8M | ||
| Q2 25 | $20.3M | $12.0M | ||
| Q1 25 | $10.1M | $35.5M | ||
| Q4 24 | $16.6M | $33.1M | ||
| Q3 24 | $28.6M | $53.9M | ||
| Q2 24 | $18.7M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $14.9M | $43.5M | ||
| Q3 25 | $27.6M | $57.0M | ||
| Q2 25 | $17.6M | $9.3M | ||
| Q1 25 | $8.4M | $26.9M | ||
| Q4 24 | $13.2M | $31.0M | ||
| Q3 24 | $27.5M | $49.8M | ||
| Q2 24 | $17.6M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | 22.1% | ||
| Q3 25 | 10.7% | 31.7% | ||
| Q2 25 | 7.3% | 5.1% | ||
| Q1 25 | 3.8% | 15.9% | ||
| Q4 24 | 6.1% | 16.6% | ||
| Q3 24 | 11.4% | 29.6% | ||
| Q2 24 | 7.8% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 0.1% | ||
| Q3 25 | 2.2% | 2.2% | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 0.8% | 5.1% | ||
| Q4 24 | 1.5% | 1.1% | ||
| Q3 24 | 0.5% | 2.4% | ||
| Q2 24 | 0.5% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.65× | — | ||
| Q3 25 | 1.36× | 11.20× | ||
| Q2 25 | 1.02× | — | ||
| Q1 25 | 0.66× | 7.37× | ||
| Q4 24 | 1.15× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.19× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
